We invite you to view the video of the recent (Nov 22, 2018) webinar discussion led by CLiC scientific committee leaders Dr. Carolyn Owen, Dr. Versha Banerji and Dr. Laurie Sehn, reviewing key questions in CLL. Click to view: http://bit.ly/2BKUBa8

CLiC Question #4: How do you transition patients from a BCRi agent to venetoclax? (2 replies to date)

CLiC Question #5: How often should you dose reduce ibrutinib for toxicity? Do you think that lower doses are better tolerated or that dose reductions are unwise? (1 reply to date)

CLiC Question #6: Which patients are appropriate for first-line ibrutinib? (no replies to date)

We invite you to review the CLiC micromodule video titled “A Summary of Discussions Surrounding CLL Treatment”, reviewing the key points of the in-depth discussions held by the CLiC community in the first half of 2018. The video is approximately 10 minutes in length.

Watch the micromodules here:

English: http://bit.ly/2KOaQGn

French: http://bit.ly/2zCzzsT

We invite you to view the video of the recent (May 9) webinar discussion led by CLiC scientific committee leaders Dr. Carolyn Owen and Dr. April Shamy, reviewing key questions in CLL. Click to view: http://bit.ly/2BKZMqQ

Please join CLiC scientific committee leaders Dr. Carolyn Owen, Dr. Graeme Fraser, and Dr. April Shamy for a webinar Wednesday, May 9, 7:00 pm EST (access info was sent to you by email on April 30) to review the recent online discussion in the CLiC community around the following questions:

• Q1: Would you be willing to change your practice to use VR in first relapse instead of ibrutinib based on the MURANO data? (3 replies to date)
• Q2: In which population should FCR still be considered the standard of care in Canada? (2 repliesto date)
• Q3: Based on currently available data, is chemo-immunotherapy an appropriate option for patients with relapsed CLL or should every patient be treated with targeted therapy at relapse? (1 reply to date)

Webinar connection details were sent to you by email on April 30 – please check your inbox. If you have any questions about the webinar or how to connect, please contact paul.abbass@legitimed.com.

Prior to the webinar, you are invited to visit the CLiC community on Sosido to review the questions & responses and to reply with your personal clinical perspectives

On behalf of Dr. Carolyn Owen (CLiC Chair) we wish to share MedViewTV and its inaugural Report from the Annual Meeting of the American Society of Hematology (ASH) Atlanta, Georgia / December 9-12, 2017, A New Era of Chemotherapy-free Treatments Emerges for Chronic Lymphocytic Leukemia (CLL) with permission from the Medical Education  Network (MedNet).

Atlanta – The recent approvals of many effective, well-tolerated novel agents for chronic lymphocytic leukemia (CLL) have changed the treatment landscape. Researchers are learning how best to sequence and potentially combine novel agents, including ibrutinib, idelalisib, and venetoclax, both with respect to chemo-immunotherapy and other novel agents. A handful of combination and single-agent CLL therapies show promising results, according to reports at ASH 2017. A major aim of CLL treatment is to eradicate detectable minimal residual disease (MRD), which is associated with improved outcomes regardless of the therapy used to achieve it. Deep remissions, including MRD negativity may be achieved with the added benefit of fixed duration of therapy. A consistent safety profile is also important to expand therapy to as many patients as possible … (more)

This week we feature coverage of the ASH 2017 Late-breaker session with Dr. John Seymour and the MURANO Study. To view, click here: http://bit.ly/2pqSLog

On behalf of the scientific committee comprised of Dr. Carolyn Owen (Chair), Dr. Graeme Fraser, and Dr. April Shamy, we’re delighted to announce the launch of a new initiative called the Canadian Leaders in CLL (CLiC).

CLiC is conceived as a learning community to raise the profile of CLL-related research being done in Canada, and to foster open scientific discussions through online forums, webinars and micro-learning modules. The intent is for members with an interest in CLL research to sustain an ongoing connection and, anchored in scientific discovery and expert insight, share clinical findings and professional perspectives to advance understanding in this field. It is our hope that enhanced communication and collaboration through this virtual community of experts will yield peer-to-peer discussions that will advance the highest level of care for CLL patients in Canada.
LegitiMed will be managing this community residing on Sosido (www.sosido.com). Learning will be structured and unstructured with specific objectives related to current & imminent topics in this field.

Some details about your participation:

• Sosido will set up your account, monitor your publications, and alert you when a new publication you’ve authored will be featured in the CLiC community;
• You will receive a weekly email digest with a summary of all new research from members of the CLiC community, as well as abstracts from relevant journals;
• You will also have access to a private online discussion forum if you wish to reach out to others in the CLiC community to ask or answer questions;
• We understand that your level of participation will be determined by your level of interest. As such, if you find that the network is not useful to you or you do not want your research to be featured, you can unsubscribe at any time.

If you are interested in participating in CLiC, please contact paul.abbass@legitimed.com

We thank AbbVie Canada for their financial support of this initiative.